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Abstract
Background: Cholesteatoma is a gradually expanding destructive epithelial lesion within the middle ear. It can cause
extensive local tissue destruction in the temporal bone and can initially lead to the development of conductive hearing loss
via ossicular erosion. As the disease progresses, sensorineural hearing loss, vertigo or facial palsy may occur. Cholesteatoma
may promote the spread of infection through the tegmen of the middle ear and cause meningitis or intracranial infections
with abscess formation. It must, therefore, be considered as a potentially life-threatening middle ear disease.
Methods and Findings: In this study, we investigated differentially expressed genes in human cholesteatomas in
comparison to regular auditory canal skin using Whole Human Genome Microarrays containing 19,596 human genes. In
addition to already described up-regulated mRNAs in cholesteatoma, such as MMP9, DEFB2 and KRT19, we identified 3558
new cholesteatoma-related transcripts. 811 genes appear to be significantly differentially up-regulated in cholesteatoma.
334 genes were down-regulated more than 2-fold. Significantly regulated genes with protein metabolism activity include
matrix metalloproteinases as well as PI3, SERPINB3 and SERPINB4. Genes like SPP1, KRT6B, PRPH, SPRR1B and LAMC2 are
known as genes with cell growth and/or maintenance activity. Transport activity genes and signal transduction genes are
LCN2, GJB2 and CEACAM6. Three cell communication genes were identified; one CDH19 and two from the S100 family.
Conclusions: This study demonstrates that the expression profile of cholesteatoma is similar to a metastatic tumour and
chronically inflamed tissue. Based on the investigated profiles we present novel protein-protein interaction and signal
transduction networks, which include cholesteatoma-regulated transcripts and may be of great value for drug targeting and
therapy development.
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Introduction
Middle ear cholesteatomas are epidermal inclusion cysts of the
middle ear or mastoid. Primary acquired cholesteatomas usually
open into the external auditory canal via a ‘defect’ in the tympanic
membrane or annulus. They contain desquamated debris com-
prising mainly keratin from their keratinizing, squamous epithelial
lining. The process of pathogenesis is still debated, but choleste-
atoma likely arises from the lateral surface epithelium of the
tympanic membrane. Middle ear cholesteatomas subsequently
grow as a self-perpetuating lesion into the middle ear spaces [1].
Numerous aetiological theories have been proposed; for example
the retraction pocket theory, the proliferation theory and
immigration theory, as well as the metaplasia theory [2,3,4]. In
general, cholesteatomas are destructive lesions that gradually
expand and lead to complications by destruction of the adjacent
structures [5].
Clinically, the onset of disease may be subtle with mild,
sometimes intermittent, symptoms. Typically, cholesteatoma
produces intermittent unilateral ear discharge, a progressive
hearing loss and may be misdiagnosed as recurrent or chronic
external otitis or otitis media. Serious complications such as facial
palsy, dizziness as well as complete deafness may occur later into
the course of the disease. Recent concepts assume that choleste-
atoma might be a disturbed wound-healing process [5], often with
an underlying inflammatory tissue repair reaction [6]. It has been
hypothesized that the development of cholesteatoma involves an
altered control of cellular proliferation, which affects the balance
towards the aggressive and invasive growth of squamous
epithelium [3]. However, it is yet unclear whether this altered
control is due to defects in the mechanisms and underlying genes
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that control proliferation, or to cytokines released from infiltrating
inflammatory cells.
The microarray method has been widely used to investigate
disease-related changes in gene expression [7,8,9]. It was the goal of
this study to investigate differential gene expression in human
cholesteatoma tissue in comparison to healthy external auditory
canal skin using a Human Gene Expression Microarray (HGEM).
The expression pattern of cholesteatoma tissue and skin samples was
analyzed byHGEMand the expression levels of selected genes were
confirmed by real-time PCR and immunohistochemistry.
Up to 811 genes were identified as up-regulated in cholestea-
toma tissue with more than 2-fold higher expression compared to
healthy skin. In comparison, 334 genes were down-regulated more
than 2-fold. Of these genes, the expression values of 33 genes were
validated using real-time PCR: 25 of these transcripts displayed
differential expression levels between the two tissue types. In 8
cases no differences in the expression were detected. Cytokeratin
6b (KRT6B) and Cytokeratin 14 immunostainings verified
increased expression levels in cholesteatoma at protein level. In
cholesteatoma matrix metalloproteinases MMP1, MMP9,
MMP10, and MMP12 were up-regulated. Interestingly, we found
transcription factors including PAX3 and Sp5, TFAP2B to be
down-regulated compared to healthy canal skin. To investigate the
potential relationship between the differentially expressed genes in
human cholesteatoma, we have started to reconstruct protein-
protein interaction and signal transduction networks using the
software application VANESA.
By using full-genome microarrays and subsequent real-time
PCR, we were able to identify several novel cholesteatoma related
genes that, after further validation, may be targets for future
therapeutic strategies.
Materials and Methods
Ethics Statement and human samples
Acquired cholesteatomas and external auditory canal skin
specimens were obtained from 17 patients undergoing middle
ear surgery at Klinikum Bielefeld Mitte (Bielefeld, Germany). Fully
informed written consent was obtained prior to surgery and all
clinical investigations were conducted according to the principles
of the Declaration of Helsinki (1964) and local guidelines
(Bezirksregierung Detmold/Mu¨nster).
Both samples (skin and cholesteatoma) were directly placed into
liquid nitrogen in the surgical theatre and stored at280uC prior to
RNA extraction.
RNA amplification labeling and hybridization to Agilent
microarrays
The commercially available Whole Human Genome (4x44)
Oligo Microarray (Agilent Technologies, Santa Clara, CA, USA)
was used in this study according to the instructions of the
manufacturer.
RNA was extracted from cholesteatoma and external auditory
canal skin using RNasy Mini Kits (Qiagen, Mississauga, ON,
Canada) according to manufacturer’s instructions. 500 ng of the
purified total RNA was subjected to T7-based amplifications using
Agilent Amp Labeling Kit to generate fluorescent cRNA. The
method uses T7 RNA polymerase, which at the same time
amplifies target material and incorporates cyanin 3- or cyanin 5-
labeled CTP. Hybridization to whole human genome microarray
gene expression chips (Agilent Technologies, Inc., Santa Clara,
CA, USA) and dye swaps (Cy3 and Cy5) was performed for RNA,
amplified from each specimen. Microarray chips were washed and
immediately scanned using a high resolution Agilent microarray
scanner G2565CA (Agilent Technologies, Inc., Santa Clara, CA,
USA).
For microarray processing, different Bioconductor software
packages (www.bioconductor.org) were used, which provide
sophisticated tools for the analysis and comprehension of high-
throughput genomic data. Primarily the LIMMA (Linear Models
for Microarray Data) [10] package was included in the in-house
developed R-analysis pipeline, that uses linear models for the
analysis of designed experiments and assessment of differential
expression. Its capabilities were used to analyze and investigate the
two-color spotted arrays and the two channel microarray
experiments.
An essential step in the analysis of the microarray data is the
quality check. In order to identify the most significant differentially
expressed genes, a background correction was initially performed.
This correction subtracts the background intensity from the
foreground intensity for each spot. Thus, it was possible to
adaptively adjust the foreground from background intensities,
which results in strictly positive adjusted intensities [11].
The Loess normalization method for the spotted microarrays
was also applied [12]. Without any normalization there can be a
considerable variation between both channels and even more
between different microarray experiments. Therefore, the M-
values for each array were separately normalized, as well as the
intensities and log-ratios between the arrays in order to compare
them across the different samples. Arrays or samples showing high
variations were excluded.
The final process step involved the application of linear models
to perform hypothesis tests. This resulted in meaningful (log2) fold
changes, standard errors, t-statistics and p-values. Using these
statistical calculations the most significant differentially expressed
genes within the samples were identified.
Microarray data discussed in this publication have been
deposited in NCBI’s Gene Expression Omnibus and are accessible
through GEO Series accession number GSE42256 (http://www.
ncbi.nlm.nih.gov/geo/query/acc.cgi?acc =GSE42256).
Real-time PCR
Total RNA was extracted from cholesteatoma and skin biopsies
using RNeasy Mini Kits (Qiagen, Mississauga, ON, Canada).
According to the manufacturer’s protocol, 0.5 mg of total RNA
was converted to cDNA using the First Strand cDNA Synthesis
Kit (Fermentas, St.Leon-Rot, Germany). Following reverse
transcription (RT) reaction, all samples were diluted 1:4 in
ddH2O and subjected to real time PCR analysis with Maxima
SYBR Green qPCR Master Mix (Fermentas, St.Leon-Rot,
Germany). 0.3 mM of gene specific primers (Table S1) were used
in a total reaction volume of 25 ml. For all targets, the cycling
conditions were: 50uC for 2 minutes, 95uC for 10 minutes,
followed by 40 cycles each consisting of 95uC for 15 seconds,
60uC for 30 seconds and 72uC for 30 seconds. Integration of
SYBR Green dye into the PCR products was monitored using the
ABI PRISM 7000 Sequence Detection System (Applied Biosys-
tems, Carlsbad, California). The Pfaffl analysis method was used to
measure the relative quantity of gene expression [13]. Serial
dilutions were performed to generate a standard curve for each
target gene in order to define the efficiency of the qPCR reaction.
The specificity of amplified PCR products was confirmed by
dissociation curve analysis (SDS software 1.1, Applied Biosystems).
The reference gene, GAPDH, was selected based on its stable
expression in all tissues analyzed. All measurements were done in
triplicates and three independent experiments were performed for
each gene target.
Cholesteatoma-Related Gene Expression Signatures
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Immunohistochemistry
Cholesteatoma and skin biopsies were fixed using 4% PFA for
60 minutes at 4 uC followed by 3 wash steps in 1xPBS for
5 minutes each. Blocking was done in 5% goat serum for
30 minutes followed by incubation with primary antibodies for
2 hours at room temperature at the following dilutions: rabbit
anti-CK5/6 1:400 (DAKO), rabbit anti-CK14 1:100 (DAKO).
Secondary, fluorochrome-conjugated antibodies were diluted
1:300 (Alexa 555) and slices were incubated for 1 hour at RT
within this solution. Nuclear counterstaining was performed using
SYTOX green, 1:20000 (Molecular Probes) for 30 minutes at RT.
The stained sections were mounted with Mowiol (Carl Roth) and
dried over night at 4uC. Fluorescence imaging was performed
using a confocal microscope (LSM 510, Carl Zeiss, and DM IRB,
Leica). Quantitative measurements of the areas of interests were
performed using Image J image analysis software (http://rsbweb.
nih.gov/ij/). Statistical significance was determined by ANOVA
with Bonferroni post hoc test, using GraphPads Prism. P 0.05 was
considered significant.
Bioinformatical network analysis
We used the in-house developed open-source software applica-
tion VANESA (www.vanesa.sf.net). VANESA aids in modeling
experimental results that can be expanded with database
information to perform modern biological network analysis [14].
In order to broaden the scope of our model, we also used
integrated databases such as HPRD, IntAct and MINT to obtain
information of interest and aid network reconstruction.
HPRD is a database of curated proteomic information
pertaining human proteins [15]. The provided information is
experimentally derived, based on mass spectrometry, protein-
microarray, protein-protein interaction, post-translational modifi-
cations (PTMs), and tissue expression. A further resource for
protein-protein interaction data is the IntAct database [16]. IntAct
provides data curated from literature and from direct data
deposits. Primarily, it consists of protein-protein interaction data.
However, it also includes protein-small molecules for other
organisms, such as Rattus norvegicus. The Molecular Interaction
Database MINT [17] was also queried as it contains approxi-
mately 235,000 interactions from over 4,800 publications. MINT
contains interactions from more than 30 different species and
provides 28,283 interactions for Homo sapiens, 4,808 for Mus
musculus, and 2,804 entries for Rattus norvegicus, which are of great
value. A detailed approach of the bioinformatic network analysis
based on the mentioned data sources will be published elsewhere
(Janowski et al. in preparation).
Results
Histology of middle ear cholesteatoma shows a mixture
of keratinous material and stratified squamous
epithelium
Histopathology displayed a mixture of keratinous material and
stratified squamous epithelium required for the diagnosis of
cholesteatoma (Fig. 1). Cholesteatoma shows bland, keratinizing,
stratified squamous epithelium and overlying keratin debris. All
examined samples demonstrated the typical histological morphol-
ogy of cholesteatoma. The epithelium displayed stratified squa-
mous epithelium with keratinization (matrix). The subepithelial
region was occupied by connective tissue (Fig. 1). The epithelium
of each sample maintained varying thickness (data not shown).
The underlying connective tissue presented a variable lympho-
plasmocytic infiltrate and appears as an inflammatory network
that triggers the cholesteatoma matrix.
Microarray analysis revealed differential gene expression
of transcripts involved in major cellular processes in
cholesteatoma
To investigate the aeitopathogenesis of cholesteatoma, we
examined cholesteatoma tissue from 17 patients undergoing
middle ear surgery using a full-genome microarray. After
determining the spot intensities at the two wavelengths, a log
ratio between the fluorescence intensities was calculated. A total of
811 up-regulated and 334 down-regulated genes in cholesteatoma
were identified using 7 selected samples from the microarray data
(Figure 2 and Figure S1). These samples were selected using the
quality criteria as above. The other samples demonstrated too high
variations in the between-array-normalization.
After filtering and data analysis, the following gene groups were
identified as demonstrating expression values at least two-fold
higher in the cholesteatoma samples compared to the healthy
tissue (Figure 2B, Table S2): 162 genes involved in signal
transduction, 156 genes in cell communication, 96 genes involved
in protein metabolism, 79 genes involved in transport processes, 70
genes related to metabolism, 70 genes related to cell growth and/
or maintenance, 66 genes involved in immune response, 65 genes
for the energy pathways, 10 relevant genes relevant for the
regulation of nucleobase, nucleoside, nucleotide and nucleic acid
metabolism, and six apoptosis genes. Biological processes with five
or less involved genes are not mentioned and denoted with ‘others’
in Figure 2B.
In contrast, 72 genes involved in signal transduction, 69 genes
involved in cell communication, 44 genes involved in cell growth
and/or maintenance, 30 genes involved in the regulation of
nucleobase, nucleoside, nucleotide and nucleic acid metabolism
nucleobase, nucleoside, nucleotide and nucleic acid, 29 genes in
transport mechanisms, 25 genes involved in energy metabolism,
25 genes involved in general metabolism, 13 genes involved in
Figure 1. Histology of cholesteatoma. Histologically, a mixture of
keratinous material and stratified squamous epithelium is required to
diagnose cholesteatoma. The epithelium displays stratified squamous
epithelium with keratinization (matrix). The subepithelial region is
occupied by connective tissue. Abbreviations: C: stratum corneum; G:
stratum granulosum; S: stratum spinosum; B: stratum basale; D: dermis.
Magnification, 600x.
doi:10.1371/journal.pone.0052718.g001
Cholesteatoma-Related Gene Expression Signatures
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Figure 2. Up-regulated and down-regulated genes in cholesteatoma. (A) mean log expression value plot. The most prominent hits are
shown in red. Microarray analysis revealed that the expression of genes, such as PI3, SPRR1B, LCN2 (lipocalin 2), MMP1, MMP9, MMP10, MMP12, SPP1,
GJB2, Bcl-xl (BCL2L1), cIAP2 (BIRC3), S100A7A (koebnerisin), S100A9, SERPINB3, CEACAM6, KRT6B and SERPINB4 is higher in cholesteatoma compared
to external auditory canal skin. Genes like TFAP2B, CDH18, CDH19, PRPH, ID4, PAX3, LAMC2, SP5 and FGFBP2 were significantly down-regulated. (B)
Up-regulated and down-regulated genes in cholesteatoma, according to biological function. Biological processes, which are denoted with ‘others’ are
processes with less than 10 genes involved.
doi:10.1371/journal.pone.0052718.g002
Cholesteatoma-Related Gene Expression Signatures
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immune response and 11 genes involved in protein metabolism
were down-regulated (Figure 2B, Table S2). Biological processes
which are denoted with ‘others’ in Figure 2B are processes where
less than 10 genes are involved.
Hierarchical clustering of the expression data
Hierarchical clustering was conducted by using significantly
regulated genes with a fold change over five. In Figure 3, 116 up-
regulated and 29 down-regulated genes are shown (Tables S3 and
S4). Significantly regulated genes were extracted from datasets and
used for hierarchical clustering. Data sets were visualized as heat
maps (Fig. 3). Hierarchical clustering reveals that the mRNA
profiles of control samples (EAS1-EAS7) differed in comparison to
cholesteatoma samples (Chole1-Chole7) concerning the expression
of inflammation-related genes such as metalloproteinases (e.g.
MMP9). It may be noteworthy to mention the strong co-
expression of MMP9 and its known substrate SPP1 (osteopontin
9). There was also a group of patients in which both MMP9 and
SPP1 demonstrated low in expression, but these maintained high
expression of genes such as S100A and GJB2. Taken together,
cluster analysis revealed a highly similar expression pattern of
control and cholesteatoma samples.
Reproducing the microarray data by real-time PCR of
representative and significant transcripts
Genes potentially involved in the aforementioned processes in
the cholesteatoma samples were analyzed by real-time PCR
(Fig. 4). The representative and significantly regulated genes with
protein metabolism activity are matrix metalloproteinases as well
as PI3, SERPINB3 and SERPINB4. Genes such as SPP1,
KRT6B, PRPH, SPRR1B and LAMC2 are known as genes with
cell growth and/or maintenance activity. Transport activity genes
and signal transduction genes are LCN2, GJB2 and CEACAM6.
Three analyzed cell communication genes are CDH19 and other
genes belonging to the S100 family. The genes relevant for the
regulation of nucleobase, nucleoside, nucleotide and nucleic acid
metabolism that seem to be regulated are TFAP2B, ID4, PAX3,
among others. SP5 and FGFBP2 as well as CXCL1 have immune
response activity. 7 apoptosis-related genes were also analyzed:
p65 (RELA), cFlip (CFLAR), Bcl-2, Bcl-xl (BCL2L1), A20
(TNFAIP3), cIAP1 (BIRC2) and cIAP2 (BIRC3)(Fig. 4B).
Real-time PCR using primers designed against message for PI3,
SPRR1B, LCN2 (lipocalin 2), MMP1, MMP9, MMP10, MMP12,
SPP1, GJB2, Bcl-xl (BCL2L1), cIAP2 (BIRC3), S100A7A
(koebnerisin), S100A9, SERPINB3, CEACAM6, KRT6B and
SERPINB4 revealed significantly higher expression levels in
cholesteatoma in comparison to auditory canal skin. Out of the
334 down-regulated genes, TFAP2B, CDH18, CDH19, PRPH,
ID4, PAX3, LAMC2, SP5 and FGFBP2 were analyzed via real-
time PCR. The results shown in Figure 4 could verify the
expression levels of these genes.
Genes for anti-apoptotic proteins such as Bcl-xl (BCL2L1), A20
(TNFAIP3) and cIAP2 (BIRC3) show only a slightly higher
expression in cholesteatoma (logFC 1.5–3) (Fig. 4B). A down-
regulation of cIAP1 (BIRC2) was observed, whereas p65 (RELA),
cFlip (CFLAR) and Bcl-2 show similar expression levels in
cholesteatoma and external auditory skin samples.
Immunohistochemistry reveals an increased Cytokeratin
expression
Cytokeratins form some of the intermediate filament proteins of
epithelial origin and can be used as makers for proliferative
keratinocytes [18]. When using antibodies against Cytokeratin 5/6
and Cytokeratin 14, strong immunoreactivity was detected in the
stratum basale and adjacent suprabasal structures. CK5/6, a
marker of basal keratinocytes and hyper-proliferation [19], is
increased in the stratum basale and in the stratum spinosum of
cholesteatoma (Fig. 5). The fluorescence signal of CK5/6 is
increased by a factor of 1.72 in cholesteatoma epithelium (Fig. 5C).
CK14, which is used as a marker of keratinizing squamous
epithelium [19], is synthesized in the basal epithelia cells.
Figure 5D shows that CK14 is increased by a factor of 1.61.
Bioinformatical network analysis
As cellular homeostasis is maintained by complex interactions of
different regulatory elements, all levels of biological structures can
be described as part of a biological network. The smallest level of
biological structure is the molecular level; DNA, RNA, proteins,
metabolites, and their interactions.
Based on experimental data and information derived from the
integrated databases, we generated model network systems in
VANESA. We linked the most significantly expressed microarray
results with database content and modeled them as biological
interaction networks (see Fig. 6, 7, and 8).
Proteins represent the nodes and the edges denote protein
activations/inactivations, such as phosphorylation and dephos-
phorylation across a set of proteins. The collected data and
information is a combination of tightly interlinked complex
systems. In particular, the database- generated networks are very
complex and difficult to analyze efficiently as the amount of data is
vast and multidimensional. Therefore, centrality measurement
techniques in VANESA were used to understand the underlying
biological processes. Centrality measurement techniques, such as
the PageRank and Clustering Algorithm demonstrated diverse
functions that are in correlation with the experimental approaches.
Using these analysis methods, the most significant topological
skeleton structures of the network could be identified and the
prominent actors and connections in cholesteatoma could be
identified. Each network is constructed using a few basic
mechanistic motifs/modules. The simulated networks demonstrate
a dynamic range of target gene activities. The network regulation
depends on additional interactions that are clearly visible in so-
called multidimensional networks. This results in a set of new,
possibly important, regulatory elements and structures that lead to
a potential extension of our knowledge of the biological system.
The analysis of the cytokeratin-expression revealed an up-
regulation of Keratin 6 A and B, Keratin 18, Keratin 19 and
Keratin 81 in cholesteatoma compared to normal skin. In
addition, Keratin 15, FAM107A, BBS1 and Peripherin were
down-regulated (Fig. 6). Within the S100 network an up-
regulation of S100A7, S100A8 and S100A9 as well as ILK and
IkB, USF2 and ARRB2 were observed, whereas NUAK1 was
down-regulated (Fig. 7). The latter presented network, the MMP
network, reveals an up-regulation of the matrix metalloproteinase
family members MMP1, 7, 9, 10, 12 as well as LCN2, IL-8 and
CXCL1. Down-regulated genes within this network were RECK,
COL4A5 and COL4A6 (Fig. 8).
In summary, the genes determined to be up regulated within
cholesteatoma indicate many possible networks involved in this
disease phenotype. The expression values mapped on the nodes
describe the pertubated information and activity flow within the
cells. These results provide potential regulatory motifs and paths,
which may represent a valuable tool for drug-targeting and
therapy after further experimental validation.
Cholesteatoma-Related Gene Expression Signatures
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Discussion
The annual incidence of cholesteatoma is around 3 cases in
100.000 children and 9 cases in 100,000 adults [20]. The diagnosis
of middle ear cholesteatoma is made on otoscopic examination,
including endoscopic and microscopic evaluation as well as
surgical exploration. Special imaging procedures, such as high-
resolution computed tomography (CT) and magnetic resonance
Figure 3. Heatmap of log expression values. For the heatmap generation, significantly regulated genes with a fold change of five were used.
116 up-regulated and 29 down-regulated genes are shown. The clustering reveals that the mRNA profiles of control samples (EAS1-EAS7) show
differences to cholesteatoma samples (Chole1-Chole7) relating to the expression of inflammation related genes such as metalloproteinases (e.g.
MMP9). The strong co-expression of MMP9 and its known substrate SPP1 (osteopontin 9) might be important. Furthermore, there was a group of
patients with low expression of both MMP9 and SPP1, but high expression of genes such as S100A and GJB2.
doi:10.1371/journal.pone.0052718.g003
Cholesteatoma-Related Gene Expression Signatures
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imaging (MRI) may suggest the presence of cholesteatomas within
the temporal bone and may be used to complement the clinical
examination. Non-EPI diffusion weighted MRI is a valuable
addition to the diagnostic tools available to identify cholesteatoma
[21]. Acquired cholesteatomas are the consequence of OME or
AOM or both. An understanding of the pathogenesis and
pathophysiology of aural cholesteatoma is important since the
destructive nature of this entity is responsible for much of the
morbidity associated with chronic otitis media. The propensity of
cholesteatoma to erode bone and the lack of effective, nonsurgical
therapy add importance to the understanding of this disease.
Lim and Saunders [22] presented a detailed histology of
cholesteatoma in 1972. They demonstrated that cholesteatoma has
a keratinized stratified squamous cell epithelium, with layers
identical to those in normal skin, Langerhans cells and kerato-
hyalin granules (‘‘cholesteatoma matrix’’). According to previous
descriptions [23], cholesteatomas are covered by keratinizing,
stratified squamous epithelium (‘‘matrix’’) of varying thickness.
These irregularities appear in cholesteatomas derived from
different patients, as well as in tissues from the same patient.
By using microarray technology, we were able to identify
differentially expressed genes in cholesteatoma compared to
healthy external auditory canal skin. Genes like DEFB2 and 3
were not evaluated due to previously published data [7]. Kwon
et al. showed 2006 that according to gene ontology, 4 cytoskeletal
genes, 4 xenobiotic metabolizing enzyme genes, 13 intracellular
protein trafficking genes, 19 apoptosis-related genes, 53 signal
transduction genes, 14 extracellular matrix/ 19 cell adhesions
genes, 7 proteinase inhibitor genes, 58 DNA/RNA binding/
transcription factor genes, 1 calcium homeostatis gene, 8
Figure 4. Real-time analysis of candidate genes. (A) The Real-time PCR analysis of potential transcripts that seem to be involved in major
processes in cholesteatoma. For normalization the housekeeping gene GAPDH was used. The real-time analysis and comparison of the expression of
different genes in external auditory canal skin and cholesteatoma confirms the results of the microarray data. In the present study, genes that encode
for MMPs and their substrate were highly up-regulated in cholesteatoma; transcripts that encode e.g. for tumor suppressors were down-regulated. (B)
Real-time analysis of apoptosis-related genes. In cholesteatoma genes for the anti-apoptotic proteins Bcl-xl (BCL2L1), A20 (TNFAIP3) and cIAP2
(BIRC3) show a somewhat higher expression. In which cIAP2 (BIRC3) appear to be down-regulated and genes for the proteins p65 (RELA), cFlip
(CFLAR) and Bcl-2 show the same expression pattern in cholesteatoma and external auditory skin.
doi:10.1371/journal.pone.0052718.g004
Cholesteatoma-Related Gene Expression Signatures
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membran protein genes, 18 cell cycle genes, and 14 immune
response genes were up-regulated in cholesteatoma samples when
compared to retroauricular skin. To study the gene expression
profile in human cholesteatoma Kwon et al. used an oligonucle-
otide chip (Macrogen, Seoul, Korea) including 10115 genes. In
contrast, in our approach we used the Agilent-platform (Agilent
Technologies, Inc., Santa Clara, CA, USA) including 10596 genes.
Microarray results often show variations depending on the
technological platform used. Indeed, in our study we were able
to show regulation of several genes related to the pathogenesis of
cholesteatoma not covered by the study of Kwon et al., such as
KRT6B, CEACAM6, SPP1, ID4, PAX3 and RECK. Derived
from these findings, we analyzed genes from different processes in
more detail: seven genes with protein metabolism activity, five
genes with cell growth and/or maintenance activity, two transport
activity genes, two signal transduction genes, and three cell
communication genes, four genes relevant for the regulation of
nucleobase, nucleoside, nucleotide and nucleic acid metabolism
and two immune response genes. Seven apoptosis and anti-
apoptosis relevant genes were also analyzed. By using real-time
PCR analysis, a panel of novel cholesteatoma related genes was
verified.
Cytokeratins, like CK6 and CK16 are known as the interme-
diate filament proteins of epithelial origin and can be used as
makers for proliferative keratinocytes [7]. Kwon et al. reported in
2006 that cytokeratin 1, 13, and 19 are up-regulated in
cholesteatoma; interestingly they did not find an up-regulation of
cytokeratin 6 or 16 [7]. Cytokeratin expression has been widely
Figure 5. Immunohistochemical staining profiles obtained with CK 5/6 (A) and CK14 (B) antibodies. Using antibodies against
Cytokeratin 5/6 and Cytokeratin 14, strong immunoreactivity was detected in the stratum basale and adjacent suprabasal structures, whereas CK5/6
is increased in the pars tensa of cholesteatoma. CK14, which is used as a marker of keratinizing squamous epithelium is synthesized in the basal
epithelia cells. (C) Statistical evaluation of CK5/6 expression in cholesteatoma stratum granulosum, stratum spinosum and stratum basale compared
to the expression within external auditory skin revealing significantly higher expression in cholesteatoma. p,0.05. (D) Comparison of CK14
expression in cholesteatoma and healthy auditory skin. The basal epithelia cells of cholesteatoma show significantly higher expression of CK14
compared to external auditory skin. p,0,04; Abbreviations: C: stratum corneum; G: stratum granulosum; S: stratum spinosum; B: stratum basale; D:
dermis; PM: peri matrix; Magnification: 400x.
doi:10.1371/journal.pone.0052718.g005
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found in various malignancies [18]. Using antibodies against
Cytokeratin 5/6 and 14, a strong signal was detected in the
stratum basale and directly adjacent suprabasal structures [24].
CK14 is synthesized in the basal epithelial cells, and is used as a
marker of keratinizing squamous epithelium [18]. Cytokeratin
expression observed in the epithelium likely explains proliferative
behavior of cholesteatoma, which is linked with increased
keratinocyte migration [25]. Keratin 14 is expressed in mitotically
active basal layer cells, along with its partner keratin 5, and their
expression is down-regulated as cells differentiate [26]. Alam et al.
showed a reduction of proliferation and a delay in cell cycle
progression, along with decreased phosphorylated Akt levels in
CK14 knockdown cells [26].
Real-time PCR of PI3, SPRR1B, LCN2 (lipocalin 2), MMP1,
MMP9, MMP10, MMP12, SPP1, GJB2, Bcl-xl (BCL2L1), cIAP2
(BIRC3), S100A7A (koebnerisin), S100A9, SERPINB3, CEA-
CAM6, KRT6B and SERPINB4 revealed that the expression
levels of these proteins were higher in cholesteatoma than in
external canal skin. Proteins of the matrix metalloproteinase
(MMPs) family are involved in the breakdown of extracellular
matrix; most MMPs are secreted under physiologic conditions.
Among the 811 up-regulated extramatrix protein genes, MMP1,
MMP7, MMp9, MMP10 and MMP12 and their substrate
Osteopontin (SPP1) were amplified and their expression was
significantly higher in cholesteatoma than in external canal skin
(logFC.10) [27]. It was observed here that the reversion-inducing
cystein-rich protein with Kazal motifs RECK is significantly down-
regulated in cholesteatoma. The RECK gene is extensively
expressed in normal tissues, but down-regulated in tumor tissues
[28,29,30]. It encodes a membrane-anchored glycoprotein and
serves as a negative regulator for metalloproteinases [30].
Furthermore PI3, which encodes Elafin (also known as peptidase
Figure 6. Bioinformatical network analysis for cytokeratin. Proteins are the nodes and the edges are protein activation/inactivations, such as
phosphorylation and dephosphorylation across a set of proteins. The cytokeratin analysis reveals an up-regulation of Keratin 6 A and B, Keratin18,
Keratin 19 and Keratin 81. In our data, genes for Keratin 15, FAM107A, BBS1 and Peripherin were down-regulated in cholesteatoma. Colors: red: up-
reglated genes within cholesteatoma compared to external auditory skin; green: down-regulated genes within cholesteatoma compared to external
auditory skin; grey: the gene for the protein is not in the microarray; Node-Size: The ‘‘Node Ranking’’ describes the number of interactions. The bigger
the nodes, the more interactions are represented for the protein in the network.
doi:10.1371/journal.pone.0052718.g006
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inhibitor 3 or skin-derived antileukoprotease (SKALP)), and its
precursor trappin-2, are potent protein inhibitors of neutrophil
serine proteases such as leukocyte elastase and proteinase 3 [31].
Alam et al. discuss the effects of elafin inhibition of neutrophil
elastase and its anti-inflammatory activity [26]. Wei et al. evaluated
the role of elafin in modulating the sensitivity of human EOC cells
to chemotherapeutic drugs [32]. Real-time PCR analysis moni-
tored a 10-fold higher expression of this gene in cholesteatoma
compared to skin. Interestingly, genes like Elafin and SPRRs form
the cornified envelope typical of squamous cells during squamous
metaplasia [33]. Cornifin-B is a protein that is encoded by the
SPRR1B gene. Its presence correlates with epidermal differentia-
tion in normal skin and skin diseases. Our results indicate that
SPRR1B expression is up-regulated in cholesteatoma compared to
skin (logFC 3). Li et al. 2008 and others reported that the synthesis
of proteins like SPRRs, loricrin, involcrin, elafin, filaggrin, and
keratins results in a change of the appearance of squamous cells.
During cholesteatoma development, these cells convert from non-
keratinizied, stratified epithelium to a nonsecretory, keratinized
epithelium [33].
Lipocalin 2 (LCN2) is known to be highly up-regulated in skin
injury and infection events [34]. Lipocalin 2 is an adipokine,
whose secretion is highly regulated by activation of inflammation
and infection, whereas lipopolysaccharide (LPS) and TNFa are
two strong inducers of LCN2 production [35]. The LCN2 was also
verified by real-time PCR, and its expression level is significantly
higher when compared to external auditory canal skin (logFC 3).
As mentioned above, SPP1 (Osteopontin) serves as a substrate for
MMPs and thrombin, it can bind to extracellular matrix proteins
(fibronectin and collagen), and is also up-regulated in cholestea-
toma (logFC 280 compared to canal skin). Additionally, the
message for anti-apoptotic proteins Bcl-xl (BCL2L1), A20
Figure 7. Bioinformatical network analysis for S100. Proteins are the nodes and the edges are protein activation/inactivations, such as
phosphorylation and dephosphorylation across a set of proteins. The S100 Network shows an up-regulation of S100A7, S100A8 and S100A9 as well as
ILK and IkB, USF2 and ARRB2. In which NUAK1 seems to be down-regulated. Different colors showing the expression of genes with the
cholesteatoma compared to external auditory skin: red: up-regulated; green: down-regulated; grey: the gene for the protein is not in the microarray;
Node-Size also called ‘‘Node Ranking’’ describes the number of interactions. The bigger the nodes, the more interactions are represented for the
protein in the network.
doi:10.1371/journal.pone.0052718.g007
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(TNFAIP3) and cIAP2 (BIRC3) show a slightly higher expression
in cholesteatoma (logFC 1.5–3) (Fig. 4B). Moreover, we observed
down-regulation of cIAP2 (BIRC3). These results correlate with
already published results [36]. They indicate that cholesteatoma
epithelium demonstrates a similar expression of differentiation and
apoptosis-related genes as does normal epithelium [36]. Calcium
Figure 8. Bioinformatical network analysis for MMPs. Proteins are the nodes and the edges are protein activation/inactivations, such as
phosphorylation and dephosphorylation across a set of proteins. The network presented here reveals an up-regulation of the matrix
metalloproteinase family members MMP1, 7, 9, 10, 12 as well as LCN2, IL-8 and CXCL1. Down-regulated genes within this network are RECK,
COL4A5 and COL4A6. The colors of the nodes describe the regulated expression of genes within cholesteatoma compared to external auditory skin:
red: up-regulated genes within cholesteatoma; green: down-regulated genes within cholesteatoma; grey: the gene for the protein is not in the
microarray; The ‘‘Node Ranking’’ (Node-Size) describes the number of interactions. The bigger the nodes, the more interactions are represented for
the protein in the network.
doi:10.1371/journal.pone.0052718.g008
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binding proteins encoded by S100A7 and S100A9 revealed a
logFC up to 29, both genes are pro-inflammatory genes. The
squamous cell carcinoma antigenes SERPINB3 (SCCA1) and
SERPINB4 (SCCA2) are circulating tumor markers for squamous
cell carcinoma. Their gene expression was also significantly higher
in cholesteatoma (logFC 5). CEACAM6 is emerging as an
important determinant of the malignant phenotype in a range of
cancers [37]; in cholesteatoma this gene is also up-regulated
(logFC 2). KRT6B is ontogenically related to cytoskeleton
formation.
Out of the 334 down-regulated genes, TFAP2B, CDH18,
CDH19, PRPH, ID4, PAX3, LAMC2, SP5 and FGFBP2 were
subsequently analyzed via real-time PCR.
We were able to demonstrate that two integral membrane
proteins, CDH18 and CDH19, from the cadherin superfamily are
down-regulated in cholesteatoma. CDH18 (also known as
Cadherin-14) is a novel neutrally specific cell-cell adhesion
molecule and may regulate neural morphogenesis. CDH19
(Cadherin-19) is of particular interest as it has been previously
shown that it is down-regulated in head and neck cancer cell lines
[38]. The ID4 gene encodes an inhibitor of the DNA binding
protein family [39]. Solid tumors, including breast, gastric and
colon cancer, as well as myelodysplasia are associated with ID4
methylation and silencing [40]. ID4 acts directly as tumor
suppressor by influencing cellular processes at multiple levels that
lead to a decreased cell proliferation [39]. However, microarray
analysis and real-time PCR reveals that this gene is significantly
down-regulated in cholesteatoma.
Members of the PAX family play critical roles during fetal
development. Alterations in the activity of the PAX3 gene are
associated with some cases of cancer in muscle tissues. PAX3 has
also been recognized as an immunogenic protein in melanomas
[41,42], inducing host immune response against PAX3-expressing
tumor cells, resulting in suppression of tumor growth [41]. PAX
genes regulate expression of cell surface molecules important for
migration [43]. PAX3 is down-regulated in cholesteatoma in both
microarray and RT-PCR analysis (Fig 4A). To date, no conclusive
case-report in published literature exists and no single case of
malignant transformation is yet known. It is, however, known that
the AP-2 protein expression levels affect cell transformation, tumor
growth and metastasis, and may predict survival in some types of
cancer [44]. It has been proposed that the loss of AP-2 is a crucial
event in the development of malignant melanoma [44]. The AP-2
transcription factor was found to be down-regulated in choleste-
atoma using both microarray and real-time PCR in our analysis.
However, the impact of these findings concerning cholesteatoma-
pathogenesis should be carefully evaluated in following studies.
Laminins are implicated in a wide range of biological processes
including cell adhesion, differentiation, growth, migration, and
proliferation [45]. Laminin-5 (LN5) consists of a3, b3 and c2
chains, which are encoded by LAMA3, LAMB3 and LAMC2
[46]. LN5 plays an important role in epithelial mesenchymal
transition through down-regulation of E-cadherin and transloca-
tion of b-cadherin into the nuclei [47]. Real-time PCR revealed
that LAMC2 is down-regulated in cholesteatomatous tissue.
The expression of Keratin suggests alterations of keratinocyte
proliferation, differentiation and migration. In the present study,
up-regulation of KRT6 A/B, KRT18, KRT19, KRT81 and
down-regulation of KRT15 was identified by microarray and
bioinformatic pathway analysis. Immunostainings of cytokeratin
revealed increased expression of CK5/6 and CK14. KRT6 and
KRT14 are specific to hyper-proliferative conditions of the
epidermis and keratinizing squamous epithelium [19]. It is known
that KRT15 is down-regulated in hyper-poliferative situations.
These results correlate with the opinion that cholesteatoma is a
proliferative middle ear disease [18], where keratinocytes express
hyperproliferative-associated cytokeratines. After reaching the
suprabasal layers they finally undergo apoptosis creating kerati-
nous debris [18].
Interestingly, there is a similarity in the gene expression of
cancer/tumor and cholesteatoma (Figure 4 and 6–8). This might
explain the aggressive behavior and local destruction of the
cholesteatoma mass compared to otitis media, even though the
local inflammatory process of chronic otitis media mesotympanalis
is similar to that of a cholesteatoma, associated with an induced
gene expression in the inflammatory pathways (Leichtle et al, in
preparation). Whereas the aggressive behavior of a cholesteatoma
mass destroys the surrounding bone and structures regardless of
tissue type and may lead to life threatening complications such as
hearing loss, facial palsy, meningitis or intracranial abscesses, a
behavior which usually is seen in malignant tumors [5].
Some authors postulate the possibility that chronic inflamma-
tion may result in a malignant transformation. However, as
cholesteatoma is a long-term chronic middle ear disease there are
no convincing clinical implications that this postulate is valid.
There are no convincing case-reports in the published literature
and no single case of malignant transformation was found in our
clinical experience (comprises app. 1.800 cases of cholesteatoma
over the last 5 years).
In summary, our results suggest that a treatment with
metalloproteinase inhibitors (such as doxycycline in a sub anti-
microbial dose) perhaps in combination with non-steroidal anti-
inflammatory drugs [48] might be a promising supportive
treatment option for non-operable cholesteatomas and is the
subject of ongoing work.
Conclusions
In this study, we have demonstrated that the cholesteatoma
tissue expresses tumor-relevant genes normally expressed in
chronically inflamed tissue. Moreover, tumor suppressor genes
CDH18, 19 and ID4, which are known to be down-regulated in
various tumors [38,49,50] PAX3, LAMC2 and TRAF2B are also
down-regulated in cholesteatoma. Genes like CEACA6, MMPs
and their inhibitor RECK [30], as well as SPRRB2 are up-
regulated.
Genes which were important for inflammation are for example
KRT 6 B, SPP1, and S100A7A are highly up-regulated in
cholesteatoma compared to external auditory skin. However,
further studies should thus evaluate a potential link between
inflammation, up-regulation of tumor-related transcripts and
cholesteatoma-pathogenesis in more detail.
This is the first report using network analysis on gene expression
signatures in cholesteatoma. We present novel protein-protein
interaction and signal transduction networks, which include
cholesteatoma-regulated transcripts and may be valuable frame-
works for drug-targeting and therapy-development.
Supporting Information
Figure S1 Normalization of RG densities. (A) Raw
densities of the selected 7 microarray samples. (B) RG densities
after normalization within the arrays. (C) RG densities after
normalization between all arrays. Summarized: After the Loess
normalization of the M-values for each array the red and green
distributions become essentially the same, which significantly
increases the expressive of the results.
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Table S1 Primers used for real-time PCR analysis.
(TIF)
Table S2 Genes related to involved processes. Listing of
significantly up- and down-regulated genes related to involved
processes within cholesteatoma compared to external auditory
canal skin.
(TIF)
Table S3 Up-regulated genes. Listing of significantly up-
regulated genes including Gene-Names, Gene-Description, logFC:
logarithmic fold change over all experiments, AveExpr: average
expression of all average-values, t: T-statistic, P.Value: p-value,
adj.P.Val: normalized p-value, and B: log Odds ratio.
(PDF)
Table S4 Down-regulated genes. Listing of significantly
down-regulated genes including Gene-Names, Gene-Description,
logFC: logarithmic fold change over all experiments, AveExpr:
average expression of all average-values, t: T-statistic, P.Value: p-
value, adj.P.Val: normalized p-value, and B: log Odds ratio.
(PDF)
Acknowledgments
We thank Dr. J.-T. Fra¨nzer for his help with the study organization and
Kyle J. Lauersen for critical reading.
Author Contributions
Conceived and designed the experiments: HS C. Klenke JK. Performed
the experiments: C. Klenke. Analyzed the data: C. Klenke SJ DB.
Contributed reagents/materials/analysis tools: TU RH C. Kaltschmidt
BK JK. Wrote the paper: C. Klenke AL JE HS SJ DW.
References
1. Sudhoff H, Stefan Dazert S, Gonzales A, Borkowski G, Park S, et al. (2000)
Angiogenesis and Angiogenic Growth Factors in Middle Ear Cholesteatoma.
The American Journal of Otology 21: 793–798.
2. Sudhoff H, Tos M (2007) Pathogenesis of sinus cholesteatoma. Eur Arch
Otorhinolaryngol 264: 1137–1143.
3. Wells M, Michaels L (1991) Mode of growth of aquired cholesteatoma.
J Laryngol Otol 105: 261–267.
4. Sudhoff H, Liang J, Dazert S, Borkowski G, Michaels L (1999) Epidermoid
formation on the pathogenesis of congenital cholesteatoma – a current review.
Laryngorhinootoligie 78: 63–67.
5. Huisman M, de Heer E, Ten Dijke P, Grote J (2008) Transforming growth
factor beta and wound healing in human cholesteatoma. Laryngoscope 118: 94–
98.
6. Shunyu N, Gupta S, Thakar A, Sharma S (2011) Histological and
immunohistochemical study of pars tensa reaction pocket. Otolaryngol Head
Neck Surg 45: 628–634.
7. Kwon KH, Kim SJ, Kim HJ, Jung HH (2006) Analysis of gene expression
profiles in cholesteatoma using oligonucleotide microarray. Acta Oto-Laryngo-
logica: 691–697.
8. Elek J, Park K, Narayanan R (2000) Microarray-based expression profiling in
prostate tumors. In Vitro 14: 173–182.
9. Yoshikawa M, Kojima H, Wada K, Tsukidate T, Okada N, et al. (2006)
Identification of specific gene expression profiles ib fibroblasts derived from
middel ear cholesteatoma. Arch Otolaryngol Head and Neck Surg 132: 734–
742.
10. Smyth GK (2005) Limma: linear models for microarray data. In: Gentleman R,
Carey V, Dudoit S, Irizarry R, Huber W, editors. Bioinformatics and
Computational Biology Solutions using R and Bioconductor. New York. 397–
420.
11. Ritchie M, Silver J, Oshlack A, Holmes M, Diyagama D, et al. (2007) A
comparison of background correction methods for two-colour microarrays.
Bioinformatics 23: 2700–2707.
12. Smyth G, Speed T (2003) Normalization of cDNA microarray data. Methods
31: 265–273.
13. Pfaffl M (2001) A new mathematical model for relative quantification in real-
time RT-PCR. Nucleic Acids Research 29.
14. Janowski s, Kormeier B, To¨pel T, Hippe K, Hofesta¨dt R, et al. (2011) Modeling
of Cell-to-Cell Communication Processes with Petri Nets Using the Example of
Quorum Sensing. Stud Health Technol Inform 162: 182–202.
15. Keshava Prasad TS, Goel R, Kandasamy K, Keerthikumar S, Kumar S, et al.
(2009) Human Protein Reference Database – 2009 Update. Nucleic Acids
Research 37: D767–D772.
16. Kerrien S, Aranda B, Breuza L, Bridge A, Broackes-Carter F, et al. (2012) The
IntAct molecular interaction database in 2012. Nucleic Acids Research 40:
D841–D846.
17. Licata L, Briganti L, Peluso D, Perfetto L, Iannuccelli M, et al. (2011) MINT,
the molecular interaction database: 2012 update. Nucleic Acids Research 40:
D857–861.
18. Olszewska E, Sudhoff H (2007) Comperative cytokeratin distribution patterns in
cholesteatoma epithelium. Histol Histopathol 22: 37–42.
19. Kim HJ, Tinling S, Chole R (2002) Expression patterns of cytokertins in
cholesteatomas: evidence of increased migration and proliferation. J Korean
Med Sci 17: 381–388.
20. Nunes LMA, Barros ALMd, Cal RVR, Nunes CTA, Lima FDd (2010) Giant
Cholesteatoma: Case and Literature Review`Report. Int Arch Otorhinolaryngol.
21. Dremmen M, Hofman P, Hof J, Stokroos R, Postma A (2012) The diagnostic
accuracy of non-echo-planar diffusion-weighted imaging in the detection of
residual and/or recurrent cholesteatoma of the temporal bone. AJNR
Am J Neuroradiol 33: 439–444.
22. Lim D, Saunders W (1972) Acquired cholesteatoma: light and electron
microscopic observations. Ann Otol Rhinol Laryngol 81: 1–11.
23. Dornelles C, Meurer L, Selaimen da Costa S, Schweiger C (2006) Histologic
description of acquired cholesteatomas: comparison between children and
adults. Braz J Otorhinolaryngol 72: 641–648.
24. Lee R, Sidey C, Narula A, James R (1994) The nature of the epithelium in
acquired cholesteatoma: part 3-cytokeratins in aural epithelial and cholesteato-
ma cells grown in cell culture. Clin Otolaryngol 19: 516–520.
25. Kim HJ, Tinling S, Chole R (2002) Increased proliferation and migration of
epithelium in advancing experimental cholesteatomas. Otol Neurotol 23: 840–
844.
26. Alam H, Sehgal L, Kundu S, Dalal S, Vaidya M (2011) Novel function of keratin
5 and 14 in proliferative and differentiation od stratified epithelial cells. Mol Biol
Cell 22: 4068–4078.
27. Makiishi-Shimobayashi C, Tsujimura T, Iwasaki T, al e (2004) Localization of
osteopontin at calcification sites of cholesteatoma: possible role as a regulator of
deposition of calcium phosphate in the middle ear. AURIS NASUS LARYNX
31: 3–9.
28. Oh J, Takahashi R, Kondo S, Mizoguchi A, Adachi E, et al. (2001) The
Membran-Anchored MMP Inhibitor RECK Is a Key Regulator of Extracellular
Matrix Integrity and Angiogenesis. Cell Press 107: 789–800.
29. Masui T, Doi R, Koshiba T (2003) RECK Expression in Panreatic Cancer: Its
Correlation with Lower Invasiveness and Better Prognosis. Clin Cancer Res 9:
1779–1784.
30. Xu J, Wu S, Xin S (2010) Expression of Matrix Metalloproteinase Regulator,
RECK, and its clinical significance in Osteosarcoma. Journal of Orthopaedic
Research 28: 1621–1625.
31. Alam S, Newby D, Henriksen P (2012) Role of the endogenous elastase
inhibitor, elafin, in cardiovascular injury: from epithelium to endothelium.
Biochem Pharmacol 83: 695–704.
32. Wei H, Hellstro¨m K, Hellstro¨m I (2012) Elafin selectvely regulates the sensitivity
of ovarian cancer cells to genotoxic druf-induced apoptosis. Gynecol Oncol 125:
727–733.
33. Li S, Nikulina K, DeVoss J, Wu AJ, Strauss E, et al. (2008) Small Proline-Rich
Protein 1B (SPRR1B) Is a Biomarker for Squamous Metaplasia in Dry Eye
Disease. Invest Ophthalimol Vis Sci 49: 34–41.
34. Li C, Chan YR (2011) Lipocalin 2 regulation and its complex role in
inflammation and cancer. Cytokine 56: 435–441.
35. Zhang J, Wu Y, Zhang Y, LeRoith D, Bernlohr D, et al. (2008) The Role of
Lipocalin 2 in the Regulation of Inflammation in Adipocytes and Macrophages.
Molecular Endocrinology 22: 1416–1426.
36. Kojima H, Miyazaki H, Tanaka Y, Shiwa M, Koga T, et al. (1999) Role of Bcl-
xL protein in differentiation and apoptosis of human middle ear cholesteatoma
epithelium. Arch Otolaryngol Head and Neck Surg 125: 735–742.
37. Duxbury M, Ito H, Benoit E, Ashley S, Whang E (2004) CEACAM6 is a
determinant of pancreatic adenocarcinoma cellular invasiveness. British Journal
of Cancer 91: 1384–1390.
38. Blons H, Laccourreye O, Houllier A, Carnot F, Brasnu D, et al. (2002)
Delineation and candidate gene mutation screening of the 18q22 minimal region
of deletion in head and neck squamous cell carcinoma. Oncogene 21: 5016–
5023.
39. Carey JP, Asirvatham AJ, Galm O, Ghogomu TA, Chaudhary J (2009) Inhibitor
of differentiation 4 (Id4) is a potential tumor suppressor in prostat cancer. BMC
Cancer 9.
40. Chen S-S, Claus R, Lucas DM, Yu L, Qian J, et al. (2011) Silencing of the
inhibitor of DNA binding protein 4 (ID4) contributes to the pathogenesis of
mouse and human CLL. Blood 117: 862–871.
Cholesteatoma-Related Gene Expression Signatures
PLOS ONE | www.plosone.org 13 December 2012 | Volume 7 | Issue 12 | e52718
41. Himoudi N, Nabarro S, Yan M, Gilmour K, Thrasher A, et al. (2007)
Development of anti-PAX3 immune responses; a target for cancer immuno-
therapy. Cancer Immunol Immunother 56: 1381–1395.
42. Medic S, Ziman M (2010) PAX3 Expression in Normal Skin Melanocytes and
Melanoytic Lesions (Naevi and Melanomas). Plos One 5.
43. Blake J, Ziman M (2003) Aberrant PAX3 and PA7 expression. A link to the
metastatic potential of embryonal rhabdomyocarcoma and cutaneous malignant
melanoma. Histol Histopathol 18: 529–539.
44. Jean D, Gershenwald J, Huang S, Luca M, Hudson M, et al. (1998) Loss of AP-2
Results in Up-regulation of MCAM/MUC18 and an Increase in Tumor
Growth and Metastasis of Human Melanoma Cells. The Journal of Biological
Cemistry 26: 16501–16508.
45. Carter W, Ryan M, Gahr P (1991) Epiligrin, a new cell adhesion ligand for
integrin alpha 3 beta 1 in epithelial basement membrans. Cell 65: 599–610.
46. Oka T, Yamamoto H, Sasaki S, Ii M, Hizaki K, et al. (2009) Overexpression of
b3/c2 chains of lamminin-5 and MMP7 in biliary cancer. World J Gastroenterol
15: 3865–3875.
47. Giannelli G, Bergamini C, Fransvea E, Sgarra C, Antonaci S (2005) Laminin-5
with transforming growth factor-beta1 induces epithelial to mesenchymal
transition in hepatocellular carcinoma. Gastroenterology 129: 1375–1385.
48. Lee H, Ciancio S, Tu¨ter G, Ryan M, Komaroff E, et al. (2004) Subantimicrobial
dose doxycycline efficacy as a matrix metalloproteinase inhibitor in chronic
periodontitis patients is enhanced when combined with a non-steroidal anti-
inflammatory drug. J Periodontol 75: 453–463.
49. Hajra K, Featon E (2002) Cadherin and catenin alterations in human cancer.
Genes Chromosomes Cancer 34: 255–268.
50. Chan A, Tsui W, Chen X, Chu K, Chan T, et al. (2003) Downregulation of ID4
by promotor hypermethylation in gastric adenocarcinoma. Oncogene 22: 6946–
6953.
Cholesteatoma-Related Gene Expression Signatures
PLOS ONE | www.plosone.org 14 December 2012 | Volume 7 | Issue 12 | e52718
